Roche, Prothena Off To PhII With Their Disease-Modifying Parkinson’s Drug

Prothena turned up at the big Alzheimer’s/Parkinson’s conference in Vienna this weekend and presented early-stage data showing how its Roche-partnered drug PRX002/RG7935 can flush out toxic clusters of alpha-synuclein in Parkinson’s patients.